Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ipratropium Bromide RESPIMAT in COPD
NCT02236182Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1998
- Primary completion
- Feb 1999
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ipratropium bromide in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Jul 1998; status: completed.
02
Drugs
ipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02236182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236182.